ⅠE期原发眼附属器黏膜相关淋巴组织淋巴瘤的放疗效果分析

doi:10.3760/cma.j.issn.1004-4221.2019.02.006

摘要
图/表
参考文献()
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

摘要目的评价ⅠE期原发眼附属器黏膜相关淋巴组织淋巴瘤放疗剂量效应和预后。方法回顾分析2003-2015年单纯放疗 93例(117只眼)ⅠE期原发眼附属器黏膜相关淋巴组织淋巴瘤患者资料。通过眼球突出度的改变观察剂量效应。采用Kaplan Meier法计算生存率并Logrank法检验和单因素预后分析。结果照射剂量≥27 Gy者眼球突出度缓解率为69%(29/42),眼球突出度缓解中位剂量7.2(5.4~19.8) Gy。全组患者局部控制率100%。全组患者5、10年总生存率分别为92%、82%,病因特异性生存率均为98%,无进展生存率分别为90%、88%。单因素分析显示国际预后指数、年龄是无进展生存的预后因素(P=0.04、0.04)。结论原发眼附属器黏膜相关淋巴组织淋巴瘤对放疗敏感。单纯放疗可以获得局部控制和长期生存。处方剂量18 Gy可以获得满意的疗效。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	赵水喜
	苏丹
	徐阳
	曹京旭
	杨新吉
	肖利华

关键词 ：眼附属器淋巴瘤/放射疗法, 剂量效应, 预后

Abstract：Objective To evaluate the dose response and prognosis of patients with stage ⅠE primary ocular adnexal mucosa associated lymphoid tissue lymphoma (POAml) treated with radiotherapy. Methods Clinical date of 93 patients (117 eyes) with stage ⅠE POAml treated from November 2003 to July 2015 were retrospectively analyzed.The dose response was evaluated by observing the ocular changes in exophthalmos. The survival rate was calculated by using the Kaplan-Meier survival analysis. The log-rank test and univariate analysis were used for prognostic analysis. Results For patients treated with a dose of ≥27 Gy,the response rate of exophthalmos was 69.0%(29/42).The median response dose was 7.2 Gy (5.4-19.8 Gy).For all patients,the local control rate was 100%.The 5-and 10-year overall survival (OS) rates were 92% and 82%.The 5-and 10-year cause-specific survival (CSS) rates were equally 98%.The 5-and 10-year progression-free survival (PFS) rate were 90% and 88%.The univariate prognostic analysis demonstrated that the International Prognostic Index (IPI) score and age were the prognostic factors of PFS rate (both P=0.04). Conclusions POAml is sensitive to radiation therapy. Radiotherapy alone can yield excellent local control and long-term survival in POAml patients. A prescription dosage of 18 Gy dose can obtain favorable clinical efficacy.

Key words： Ocular adnexal lymphoma/radiotherapy Dose response Prognosis

收稿日期: 2018-06-11

引用本文:

赵水喜,苏丹,徐阳等. ⅠE期原发眼附属器黏膜相关淋巴组织淋巴瘤的放疗效果分析[J]. 中华放射肿瘤学杂志, 2019, 28(2): 108-112.

Zhao Shuixi,Su Dan,Xu Yang et al. Clinical efficacy of radiotherapy for stage ⅠE Primary ocular adnexal mucosa associated lymphoid tissue lymphoma[J]. Chinese Journal of Radiation Oncology, 2019, 28(2): 108-112.

链接本文:

http://journal12.magtechjournal.com/Jweb_fszlx/CN/10.3760/cma.j.issn.1004-4221.2019.02.006 或 http://journal12.magtechjournal.com/Jweb_fszlx/CN/Y2019/V28/I2/108

[1] Le QT,Eulau SM,George TI,et al. Primary radiotherapy for localized orbital MALT lymphoma[J].Int J Radiat Oncol Biol Phys,2002,52(3):657-663.
[2] Fung CY,Tarbell NJ,Lucarelli MJ,et al. Ocular adnexal lymphoma:clinical behavior of distinct world health organization classification subtypes[J].Int J Radiat Oncol Biol Phys,2003,57(5):1382-1391
[3] Uno T,Isobe K,Shikama N,et al. Radiotherapy for extranodal,marginal zone,B-cell lymphoma of mucosa-associated lymphoid tissue originating in the ocular adnexa[J].A multⅡnstitutional,retrospective review of 50 patients. Cancer,2003,98(4):865-871.DOI:10.1002/cncr.11539.
[4] Lee JL,Kim MK,Lee KH,et al. Extranodal marginal zone B-cell lymphomas of mucosa-associated lymphoid tissue-type of the orbit and ocular adnexa[J].Ann Hematol,2005,84(1):13-18.DOI:10.1007/s00277-004-0914-3.
[5] Zhou P,Ng AK,Silver B,et al. Radiation therapy for orbital lymphoma[J].Int J Radiat Oncol Biol Phys,2005,63(3):866-871.DOI:10.1016/j.ijrobp.2005.03.005.
[6] Aviles A,Neri N,Calva A,et al. Addition of a short course of chemotherapy did not improve outcome in patients with localized marginal B-cell lymphoma of the orbit[J].Oncology,2006,70(3):173-176.DOI:10.1159/000093804.
[7] Suh CO,Shim SJ,Lee SW,et al. Orbital marginal zone B-cell lymphoma of MALT:radiotherapy results and clinical behavior[J].Int J Radiat Oncol Biol Phys,2006,65(1):228-233.DOI:10.1016/j.ijrobp.2005.11.035.
[8] Ejima Y,Sasaki R,Okamoto Y,et al. Ocular adnexal mucosa-associated lymphoid tissue lymphoma treated with radiotherapy[J].Radiother Oncol,2006,78(1):6-9.DOI:10.1016/j.radonc.2005.11.005.
[9] Nam H,Ahn YC,Kim YD,et al. Prognostic significance of anatomic subsites:Results of radiation therapy for 66 patients with localized orbital marginal zone B cell lymphoma[J].Radiother Oncol,2009,90(2):236-241.DOI:10.1016/j.radonc.2008.09.011.
[10] Son SH,Choi BO,Kim GW,et al. Primary radiation therapy in patients with localized orbital marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)[J].Int J Radiat Oncol Biol Phys,2010,77(1):86-91.DOI:10.1016/j.ijrobp.2009.04.018.
[11] Hata M,Omura M,Koike I,et al. Treatment effects and sequelae of radiation therapy for orbital mucosa-associated lymphoid tissue lymphoma[J].Int J Radiat Oncol Biol Phys,2011,81(5):1387-1393.DOI:10.1016/j.ijrobp.2010.07.1992.
[12] Goda JS,Le LW,Lapperriere NJ,et al. Localized orbital mucosa-associated lymphoma tissue lymphoma managed with primary radiation therapy:efficacy and toxicity[J].Int J Radiat Oncol Biol Phys,2011,81(4):e659-666.DOI:10.1016/j.ijrobp.2011.03.050.
[13] Hashimoto N,Sasaki R,Nishimura H,et al. Long-term outcome and patterns of failure in primary ocular adnexal mucosa-associated lymphoid tissue lymphoma treated with radiotherapy[J].Int J Radiat Oncol Biol Phys,2012,82(5):1509-1514.DOI:10.1016/j.ijrobp.2011.04.052.
[14] Ohja S,Nakamura K,Shioyama Y,et al. Treatment outcome of radiotherapy for localized primary ocular adnexal MALT lymphoma-prognostic effect of the AJCC Tumor-Node-Metastasis clinical staging system[J].Anticancer Res,2015,35(6):3591-3597.
[15] Lam AK,Lam CF,Leung WK,et al. Intra-observer and inter-observer variation of Hertel exophthalmometry[J].Ophthalmic Physiol Opt,2009,29:472-476.DOI:10.1111/j.1475-1313.2008.00617.x.
[16] Dickinson AJ,Gausas RE.Orbital lymphatics:do they exist?[J].Eye,2006,20(10):1145-1148.DOI:10.1038/sj.eye.6702378.
[17] Pfeffer MR,Rabin T,Tsvang L,et al. Orbital lymphoma:Is it necessary to treat the entire orbit[J]? Int J Radiat Oncol Biol Phys,2004,60(2):527-530.DOI:10.1016/j.ijrobp.2004.03.039.
[18] Jung SK,Paik JS,Jung SE,et al. Suggestion of response evaluation criteria in patients with ocular adnexal mucosa-associated lymphoid tissue lymphoma (OAml)[J].Ann Hematol,2015,94(7):1185-1193.DOI:10.1007/s00277-015-2339-6.
[19] Lowry L,Smith P,Qian W,et al. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma:A randomised phase Ⅲ trial[J].Radiother Oncol,2011,100(1):86-92.DOI:10.1016/j.radonc.2011.05.013.
[20] Hoskin PJ,Kirkwood AA,Popova B,et al.4 Gy versus 24 Gy radiotherapy for patients with indolentlymphoma (FORT):a randomised phase 3 non-inferiority trial[J].Lancet Oncol,2014,15(4):457-463.DOI:10.1016/S1470-2045(14)70036-1.
[21] Bolek TW,Moyses HM,Marcus RB,et al. Radiotherapy in the management of orbital lymphoma[J].Int J Radiat Oncol Biol Phys,1999,44(1):31-36.
[22] Harada K,Murakami N,Kitaguchi M,et al. Localized ocular adnexal mucosa-associated lymphoid tissue lymphoma treated with radiation therapy:a long-term outcome in 86 patients with 104 treated eyes[J].Int J Radiat Oncol Biol Phys,2014,88(3):650-654.DOI:10.1016/j.ijrobp.2013.11.235.McKelvie PA,McNabA,Francis IC,et al. Ocular adnexal lymphoproliferative disease:a series of 73 cases[J].Clin Exper Ophthal,2001,29(6):387-393.
[23] Henk JM,Whitelocke RA,Warrington AP,et al. Radiation dose to the lens and cataract formation[J].Int J Radiat Oncol Biol Phys,1993,25(5):815-820.